Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Enrolling by invitation 1

Sponsor Class

INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 31Other solid neoplasm 10Sarcoma 7Gynecologic 6Gastrointestinal 4Breast 4Tumor-Agnostic 3NET 3Endocrine 3Other hematologic neoplasm 1Genitourinary 1CNS 1

Conditions

Neuroendocrine Tumors 3Neoplasms 2Stomach Neoplasms 1Sarcoma 1Mesothelioma 1Glioblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Adenoma, Islet Cell 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
PM 01183 × Endocrine × Clear all
NCT07121478 2025-10-01

Patients With High-grade Pancreatic Neuroendocrine Tumors

National Cancer Center, Korea

Phase 2 Enrolling by invitation
46 enrolled
EndocrineNET

Adenoma, Islet Cell, Neuroendocrine Tumors

NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

NCT01970540 2020-03-09

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

PharmaMar

Phase 1 Completed
122 enrolled 19 charts
EndocrineNET

Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡